Article Details
Retrieved on: 2021-07-06 08:46:04
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Alexion's portfolio of rare disease meds includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody and ...
Article found on: www.pharmatimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here